Lab21 Buys Fungal Molecular Diagnostics Firm Myconostica | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Lab21 today announced it has acquired fungal molecular diagnostic firm Myconostica for an undisclosed amount.

The deal will expand Lab21's portfolio of diagnostics and will provide it with its first nucleic acid-based assays. It also provides Lab21 with manufacturing capabilities to develop and produce a range of new biomarker assays, the Cambridge, UK-based firm said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Biology this week: comparative genomics study of Aspergillus, genetic variation in indigenous African cattle, and more.

Some people who harbor genetic variants associated with disease show no signs and may give insight into the continuum of symptoms, Spectrum reports.

Some 57 snow monkeys at a Japanese zoo were found to be rhesus macaque hybrids, which are banned in Japan.

British researchers say they've been removed from EU grant applications, according to the Guardian.